US · Healthcare · Biotechnology
EPS came in at -1.10 against a street estimate of -1.21 — a beat of 9.1%.
Analysts rate Viking Therapeutics Inc a buy (17 buy, 2 hold, 0 sell out of 19) with an average price target of $92.39.
CONFIDENT Viking advanced VK2735 (dual GLP-1/GIP agonist) Phase III trials on track with full enrollment; launched oral formulation Phase III in Q4; initiated VK3019 amylin agonist Phase I; maintained $502M cash; no revenue yet. Q2 2026 No geographic segments discussed on call. Analysts pressed design specifics (oral size, maintenance breakouts, AE reporting) and VK3019 strategy. Management acknowledged maintenance trial is not designed for early safety signals (known tolerability risk is front-loaded), confirmed oral Phase III is smaller, and noted amylin combo requires 2027+ timeline and Phase I/II safety data. 2026-07-29…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 5.90% |
| FMR Inc | 5.16% |
| Vanguard Capital Management, LLC | 4.30% |
| Vanguard Portfolio Management, LLC | 3.83% |
| State Street Corp | 3.77% |
| Two Sigma Investments LLC | 3.38% |
| Morgan Stanley - Brokerage Accounts | 2.58% |
| Geode Capital Management, LLC | 1.78% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 VIKING THERAPEUTICS, INC. — 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Cash and short-term investments combined: $501.7 million as of June 30, 2026 ( | 2026-07-29 |
| Results announced · Q3 2026 VIKING THERAPEUTICS Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash position: $502 million in cash, cash equivalents, and short-term investments a | 2026-07-29 |
| Shareholder vote results · Q2 2026 VIKING THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held May 19, 2026 • 115,893,943 total shares outstanding as of March 20, 2 | 2026-05-26 |
| Quarterly report · Q1 2026 VIKING THERAPEUTICS, INC. — 10-Q SUMMARY (Q1 2026) HEADLINE NUMBERS • Cash and short-term investments combined: $602.964 million (March 31, 2026), d | 2026-04-30 |
| Results announced · Q2 2026 VIKING THERAPEUTICS Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash position: $603 million in cash, cash equivalents and short-term invest | 2026-04-29 |
| Proxy statement · Q2 2026 VIKING THERAPEUTICS, INC. — 2026 PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1 — Election of Directors: Elect two Class II di | 2026-04-01 |
| Annual report FY2025 VIKING THERAPEUTICS, INC. – 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Company: Viking Therapeutics, Inc. (NASDAQ: VKTX) – clinical-stage | 2026-02-11 |
| Results announced · Q1 2026 VIKING THERAPEUTICS – Q4 & FULL-YEAR 2025 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash position: $706 million in cash, cash equivalents and short-term | 2026-02-11 |
Readable in the app.
| Announcement | Date |
|---|---|
| Phase 3 obesity trial enrollment complete; oral formulation advancing to Phase 3 Viking Therapeutics, a clinical-stage biotech company, announced strong progress on its obesity drug pipeline. The company's lead candidate VK2735—a dual GLP-1/GIP receptor agonist—completed | 2026-02-11 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Viking Therapeutics Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.